TxGemma is a set of open Al models designed to enhance drug development efficiency by leveraging the power of large language models. TxGemma has been made available to the community through the Health Al DeveloperFoundations platform. The models' license terms are not yet clear. In October,Google launched Tx-LLM, a language model designed for various therapeutic tasks in drug development. Due to strong interest, after fine-tuning the model for therapeutic applications, Google has now created its open successor,TxGemma. TxGemma allows developers to customize it for their owntherapeutic data and tasks.

At the NVIDIA GTC conference in San Jose, CEO Jensen Huangaddressed over 25,000 attendees, emphasizing Al's growing impact across industries, including healthcare. The event featured major Al-driven advancements in drug discovery, such as NVIDIA BioNeMo's updates and integration into platforms like Sapio ELN and Orion for molecular modelingand protein synthesis prediction. NVIDIA also unveiled Evo 2, the largestpublicly accessible Al model for biology, developed with the Arc Institute.NVIDIA's collaboration with ConcertAl is pioneering Al "agents" to streamline oncology research and clinical trial workflows. These modelsautomate complex tasks such as extracting biomarker data and optimizing trial designs. The partnership leverages NVIDIA's computational power to scale agent-driven automation, reducing administrative burdens and enhancing decision-making in drug development.

Insilico Medicine and Enveda have both secured significant funding to advance Aldriven drug discovery. Enveda leverages Al to discover new medicines from naturalsources, while Insilico Medicine integrates generative Al, biology, and chemistry to optimize drug development, featuring tools like a humanoid Al scientist and roboticlab automation. Insilico raised $110 million to enhance its Pharma.Al platform androbotic research lab, while Enveda gained backing from Sanofi, bringing its total Series C financing to $150 million to support clinical trials for its Al-discovered therapies. These investments highlight the growing role of Al in pharmaceutical innovation, with major players like Sanofi and Menarini Group partnering with Aldriven startups to accelerate drug development.

The Oxford Drug Discovery Institute is using Al-powered databases and knowledge graphs to accelerate Alzheimer's drug discovery by rapidlyanalyzing vast biomedical datasets. By leveraging these technologies,researchers have reduced the time needed to evaluate gene targets from weeks to days, improving the selection of potential drug targets.Knowledge graphs help scientists trace biological relationships across multiple sources, enhancing data interpretation and target identification.

Scientists at The Institute of Cancer Research, London, have developed an Al-powered "fingerprint" technology that analyzes the3D shape of cancer cells to determine how they respond to new drugs. Unlike previous 2D imaging methods, this tool uses nearly100,000 3D images of melanoma cells and deep learning to predictdrug effects with up to 99.3% accuracy. The researchers havepatented the tool and launched a spinout company, Sentinal4D, to further develop and integrate it into the drug discovery process,potentially benefiting a wide range of diseases beyond cancer.

The FDA has released draft guidance on Al use in drug and biological product development, outlining a risk-based framework for evaluating Almodel credibility. The guidance defines "context of use" to determine Al's role in decision-making and the level of disclosure required, with high-risk models needing extensive transparency regarding data, training,validation, and governance. Additionally, it presents opportunities for innovation, particularly in Al explainability, bias detection, life cycle monitoring, and compliance tools. The guidance remains open for publiccomment until April 7, 2025.